Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Biogen
Biogen
PhRMA cries foul on CMS' registry approach for Alzheimer's disease drugs
Fierce Pharma
Sun, 06/4/23 - 04:15 pm
Biogen
Eisai
Alzheimer's disease Leqembi
CMS
PhRMA
Medicare outlines plan to expand coverage for costly new Alzheimer’s drugs
Washington Post, DC
Fri, 06/2/23 - 10:18 am
Medicare
Alzheimer's disease
Eisai
Biogen
Leqembi
Quanterix sees a bright future for blood biomarkers
EP Vantage
Fri, 06/2/23 - 10:08 am
Biogen
Quanterix
diagnostics
Qalsody
ALS
biomarkers
The Alzheimer's pipeline is as strong as ever. Now, we just need the patients
Fierce Biotech
Wed, 05/31/23 - 07:02 pm
Alzheimer's disease
patients
clinical trials
Biogen
Eisai
Eli Lilly
Go or no go? Key FDA decisions for Argenx and Regeneron
EP Vantage
Wed, 05/31/23 - 10:51 am
FDA
Albireo Pharma
Aldeyra Therapeutics
Alvotech
Amneal Pharmaceuticals
Argenx
ARS Pharmaceuticals
AstraZeneca
Bayer
Bio-Thera Solutions
Biogen
BioMarin Pharmaceutical
Bristol Myers Squibb
Eisai
Eton Pharmaceuticals
F2G
Fabre-Kramer Pharmaceuticals
Fresenius
GSK
Intercept Pharmaceuticals
Ipsen
Ironwood Pharmaceuticals
Merck
Novaliq
Pfizer
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Takeda
Teva Pharmaceutica
UCB Pharma
Amyloid-Beta Structure Revelation Sheds Light on Leqembi’s Function
BioSpace
Wed, 05/24/23 - 06:51 pm
Eisai
Biogen
Alzheimer's disease
Leqembi
amyloid beta
JAMA: Leqembi could cost Medicare up to $5B per year
Medical Marketing and Media
Mon, 05/15/23 - 06:20 pm
Biogen
Eisai
Leqembi
drug pricing
Medicare
Alzheimer's disease
JAMA
2023’s biggest launches: the story so far
EP Vantage
Fri, 05/12/23 - 10:19 am
drug launches
AbbVie
Almirall
Apellis Pharmaceuticals
Astellas
AstraZeneca
Biogen
CRISPR Therapeutics
Daiichi Sankyo
Eli Lilly
Genmab
GSK
Iveric Bio
Pfizer
Roche
SAGE Therapeutics
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Vertex Pharmaceuticals
Biogen, Novartis, Sanofi Cull Candidates in Q1 Pipeline Reprioritizations
BioSpace
Fri, 05/5/23 - 12:09 pm
Biogen
Novartis
Sanofi
earnings
R&D
Biogen chalks up a Tecfidera patent win in Europe after losing US protections
Fierce Pharma
Fri, 05/5/23 - 11:50 am
Biogen
Tecfidera
multiple sclerosis
Europe
Biogen paid CEOs Viehbacher, Vounatsos $57M in 2022
Medical Marketing and Media
Mon, 05/1/23 - 10:08 pm
Biogen
Pharma CEOs
executive compensation
Will Biogen’s Qalsody Be a Catalyst for Gene-Specific ALS Research?
BioSpace
Thu, 04/27/23 - 11:51 am
Biogen
Qalsody
tofersen
ALS
drug development
R&D
Biogen isn’t concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says
CNBC
Wed, 04/26/23 - 09:59 am
Biogen
earnings
Pharma CEOs
Chris Viehbacher
Eli Lilly
Alzheimer's disease
Leqembi
donanemab
FDA approves Biogen and Ionis’ Tofersen for rare genetic form of ALS
Medical Marketing and Media
Tue, 04/25/23 - 10:20 pm
Biogen
Ionis Pharmaceuticals
ALS
tofersen
FDA
Busy with 3 program launches this year, Biogen trims pipeline
Fierce Biotech
Tue, 04/25/23 - 11:40 am
Biogen
stroke
gene therapy
ophthalmology
earnings
Finding the big spenders beyond big pharma
EP Vantage
Mon, 04/24/23 - 10:15 am
R&D
Amgen
Bayer
Biogen
Gilead Sciences
Merck KGaA
Moderna Therapeutics
Novo Nordisk
Regeneron Pharmaceuticals
UCB
Vertex Pharmaceuticals
Big pharma holds steady on research spending
EP Vantage
Fri, 04/21/23 - 10:03 am
R&D
AbbVie
Amgen
AstraZeneca
Bayer
Biogen
Bristol Myers Squibb
Eli Lilly
Gilead Sciences
GSK
JNJ
Merck
Merck KGaA
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
UCB
Vertex Pharmaceuticals
Biogen buys into Denali’s amyloid beta program
Pharmaphorum
Thu, 04/13/23 - 10:05 am
Biogen
Denali Therapeutics
Alzheimer's disease
In Another Round of Cuts, Biogen Lays Off Unspecified Number of Employees
BioSpace
Mon, 04/10/23 - 12:00 pm
Biogen
layoffs
5 FDA decisions to watch in the second quarter
BioPharma Dive
Mon, 04/3/23 - 11:06 pm
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Biogen
tofersen
ALS
Seres Therapeutics
C. difficile
Pfizer
GSK
vaccines
RSV
Regeneron
Eylea
Pages
« first
‹ previous
…
3
4
5
6
7
8
9
10
11
…
next ›
last »